Tranquis Therapeutics

About:

Tranquis Therapeutics is focused on the discovery and development of therapies to treat neurodegenerative and aging-related diseases.

Website: https://www.tranquis.com/

Twitter/X: tranquistx

Top Investors: Correlation Ventures, SR One, Vivo Capital, Remiges Ventures, Hillsborough Venture

Description:

Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide. Founded on groundbreaking neuro-immunology research from the laboratory of Professor Edgar Engleman, MD, at Stanford University, Tranquis’ novel therapeutic approach targets underlying myeloid immune cell dysfunction that has been linked to a variety of nervous system disorders. The company’s portfolio is comprised of small molecules which cross the blood-brain barrier, and the lead therapeutic candidate has demonstrated highly encouraging effects in challenging preclinical models of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s Disease (PD), and age-related cognitive impairment. Tranquis plans to initiate development in orphan neurodegenerative diseases such as ALS and FTD and later expand into more prevalent diseases such as PD and Alzheimer’s Disease.